Acne varioliformis
Methodology & AI Transparency ⓘ
Acne varioliformis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Acne varioliformis is an ICD-10-CM indexed diagnosis (L70.2) within Dermatology: Acne, Eczema, Psoriasis & Rosacea.
- 2 Real-world patient consensus: Federal ICD-10-CM code L70.2 categorizes Acne varioliformis under Dermatology: Acne, Eczema, Psoriasis & Rosacea.
- 3 Typical cash cost range: Clinicians assessing Acne varioliformis focus on or pilosebaceous follicular in Acne varioliformis (L70.2: hyperkeratinization) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Acne varioliformis: Fasting Lipids & in Acne varioliformis (L70.2: ALT (if systemic) (Within baseline reference limits (L70.2)) and 25-Hydroxy Vitamin D in Acne varioliformis (L70.2: & hs-CRP).
Ask our AI Specialists anything about Acne varioliformis
What Is Acne varioliformis?
Acne varioliformis is an ICD-10-CM indexed diagnosis (L70.2) within Dermatology: Acne, Eczema, Psoriasis & Rosacea. Clinical evaluation centers on dermoscopy or punch in Acne varioliformis (L70.2: biopsy when atypical) alongside serial Fasting Lipids & in Acne varioliformis (L70.2: ALT (if systemic) tracking (Within baseline reference limits (L70.2)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Acne varioliformis (ICD-10 L70.2) is driven by or pilosebaceous follicular in Acne varioliformis (L70.2: hyperkeratinization); specialists in Dermatology: Acne, Eczema, Psoriasis & Rosacea monitor 25-Hydroxy Vitamin D in Acne varioliformis (L70.2: & hs-CRP) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Acne varioliformis (L70.2): persistent erythematous plaques, in Acne varioliformis (L70.2: scaly patches, pruritic)
- • Secondary Acne varioliformis clinical sign: compromised epidermal barrier in Acne varioliformis (L70.2: with dryness, fissuring,)
- • Symptom flares in Acne varioliformis correlating with Fasting Lipids & in Acne varioliformis (L70.2: ALT (if systemic) deviation outside Within baseline reference limits (L70.2)
- • Functional skin & dermatology impact requiring dermoscopy or punch in Acne varioliformis (L70.2: biopsy when atypical) evaluation (L70.2)
Acne varioliformis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L70.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Lipids & in Acne varioliformis (L70.2: ALT (if systemic) | Within baseline reference limits (L70.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Acne varioliformis (L70.2: & hs-CRP) | 25(OH)D 40–65 ng/mL (L70.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Acne varioliformis (L70.2: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L70.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Acne varioliformis
Treatment selection for Acne varioliformis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Acne varioliformis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Skin-applied tazarotene in the treatment of mild to moderate: What a 468-Participant Study Found In general, 'using the cream formulation rather than the gel formulation optimized tolerability. Cutis • 2004-10-15 • Meta-Analysis | N = 468 | 97/100 | PMID 15543714 ↗ |
| New Insights on Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients: What a 1,614-Participant Study Found Once-daily treatment with tazarotene 0.045% polymeric emulsion lotion may help improve patient-perceived skin oiliness in those with moderate-to-severe acne. The Journal of dermatological treatment • 2023-12-15 • Randomized Controlled Trial | N = 1,614 | 96/100 | PMID 36382987 ↗ |
| New Insights on Janus kinase inhibitors and side effects of acne in dermatologic: What a 11,396-Participant Study Found Conclusions: There are higher rates of acne following treatment with JAK inhibitors for dermatologic indications, particularly with longer durations and larger dosages. The Journal of dermatological treatment • 2024-12-15 • Meta-Analysis | N = 11,396 | 94/100 | PMID 39218446 ↗ |
| New Insights on Gold-standard blind, vehicle-controlled, multicenter comparison of two 0.025%: What a 271-Participant Study Found The commercially-available 0.025% tretinoin cream and the 0.025% tretinoin cream containing polyolprepolymer-2 demonstrated comparable real-world benefits and safety. Journal of the American Academy of Dermatology • 1998-04-15 • Randomized Controlled Trial | N = 271 | 93/100 | PMID 9555823 ↗ |
| New Insights on Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily: What a 551-Participant Study Found Conclusions: Tretinoin 0.05% lotion was significantly more effective than vehicle in achieving treatment success and reducing inflammatory and noninflammatory lesions in adult females with moderate acne, with notable... Journal of drugs in dermatology : JDD • 2019-11-01 • Randomized Controlled Trial | N = 551 | 93/100 | PMID 31741360 ↗ |
Acne varioliformis Patient Community & “People Like Me” Threads
Filter Acne varioliformis community threads and patient logs by age, biological sex, dosage, and treatment duration.